DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Ofatumumab
Ofatumumab
Activity of Rituximab and Ofatumumab Against Mantle
Refreshing the Biologic Pipeline 2020
Whither Radioimmunotherapy: to Be Or Not to Be? Damian J
B-Cell Targets to Treat Antibody-Mediated Rejection In
Evaluation of Next-Generation Anti-CD20 Antibodies Labeled with Zirconium 89 In
One Target, Different Effects: a Comparison of Distinct Therapeutic Antibodies Against the Same Targets
Hodgkin's Lymphoma Unresponsive to Rituximab Or a Rituximab
Ofatumumab for the Treatment of Patients with Chronic Lymphocytic Leukemia Refractory to Fludarabine and Alemtuzumab
Antibodies for the Treatment of Brain Metastases, a Dream Or a Reality?
Ofatumumab in RMS • BTD for Janssen’S JNJ-61186372 (Amivantamab) • Anthony Pagano Appointed to CFO and Anthony Mancini Appointed to Newly Created Position of COO
The Role of Monoclonal Antibodies in the Management of Leukemia
2.03.502 Monoclonal Antibodies for the Treatment of Lymphoma
Lemtrada (Alemtuzumab)
Treating the Hodgkin's Lymphoma Variant of Richter's Transformation
Ofatumumab Exhibits Enhanced in Vitro and in Vivo Activity Compared to Rituximab in Pre- Clinical Models of Mantle Cell Lymphoma
Australian Public Assessment Report for Trastuzumab
Evaluation of Next-Generation Anti-CD20 Antibodies Labeled with 89Zr in Human Lymphoma Xenografts
Injectable and Health Care Administered Oncology Medical Drug Criteria Through Preferred (Optional)
Top View
Injectable Anti-Cancer Medications
Cytokine Release Syndrome (CRS)
Abstract #630 Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed Or Refractory Diffuse Large B-Cell Lymphoma: the Orcharrd Study (OMB110928)
Randomised Controlled Trial Comparing Ofatumumab to Rituximab
Non-Hodgkin Lymphoma Therapy Landscape
Arzerra® (Ofatumumab) (Intravenous) -E- Document Number: MODA-0469 Last Review Date: 05/03/2021 Date of Origin: 06/2019 Dates Reviewed: 06/2019, 05/2020, 05/2021
Bladder Cancer
Standard and Novel Therapeutic Hematology Agents for the New Advanced Practice Provider
Ofatumumab Exhibits Enhanced in Vitro and in Vivo Activity Compared to Rituximab in Preclinical Models of Mantle Cell Lymphoma Matthew J
2.03.502 Monoclonal Antibodies for the Treatment of Lymphoma
Development of Novel Anti-Cd20 Monoclonal Antibodies And
099 Quality Care Cancer Program (Medical Oncology)
Uses of Monoclonal Antibodies for the Treatment of Non-Hodgkin
Mechanisms of Resistance to Monoclonal Antibodies (Mabs) in Lymphoid Malignancies
Cardiotoxicity of Novel Targeted Hematological Therapies
Specialty Injectables Prior Authorization List
Lenalidomide, Dexamethasone And
Genmab Announces Financial Results for the First Half of 2021
Rituximab Hypersensitivity Reactions and Tolerance of Ofatumumab Therapy
Genmab Announces Completion of Agreement to Transfer Remaining Ofatumumab Rights
Adult Antiemetic Management of Chemotherapy-Induced Nausea
Connecticare Commercial Connecticare Commercial J7192 Advate (Factor VIII)
Oncology Medications Policy (1403)
Systematic Review on Infusion Reactions to and Infusion Rate of Monoclonal Antibodies Used in Cancer Treatment MAURIEN D
Current Specialty Pharmacy Drugs (As of July 1, 2021*) New Drugs Indicated in Red
Oncology Therapy for the Generalist
Monoclonal Antibodies in the Treatment of Non-Hodgkin's
MP-2.139 Uses of Monoclonal Antibodies for the Treatment of Non
CHMP Agenda of the 25-29 January 2021 Meeting
Arzerra® (Ofatumumab)
June 30, 2021 Total Approvals 269 This Report Will Be Updated January and July of Every Year
(Arzerra®) for the Treatment of Chronic Lymphocytic Leukaemia in Patients Who Are Refractory to Fludarabine and Alemtuzumab: a Critique of the Submission from GSK
Linear Epitopes That Generate Anti-Her-2 Antibody Responses with Trastuzuab- (Herceptin) Like Biological Activity
List Item Applications for New Human
Anti-CD20 Agents for Multiple Sclerosis: Spotlight on Ocrelizumab and Ofatumumab
Ofatumumab, a Second- Generation Anti-CD20 Monoclonal Antibody, For
Kesimpta® (Ofatumumab, Formerly OMB157)
Specialty Pipeline Monthly Update June 2021
MEDICAL DRUGS PRIOR AUTHORIZATION LIST Effective 1/22/2021
Specialty Pipeline MONTHLY UPDATE
ARZERRA Safely and Effectively
Toga: Trastuzumab with Standard Chemotherapy for HER2-Positive Advanced Gastric Cancer (GC)
Monoclonal Antibodies for Non-Hodgkin Lymphoma and Acute Myeloid Leukemia in the Non-Hematopoietic Stem Cell Transplant Setting
(Ofatumumab) in Fludarabine and Alemtuzumab Refractory Chronic Lymphocytic Leukemia
Ofatumumab for the Treatment of Chronic Lymphocytic Leukemia
Monoclonal Antibodies in Cancer Therapy
Radioimmunotherapy Consolidation Using I-Tositumomab for Patients
Impact of Epidermal Growth Factor Receptor (EGFR) Cell Surface
ECTRIMS Data Investor Call
Hypersensitivity to Biological Agents-Updated Diagnosis
Publication Agenda CHMP 07-10 December 2020
Arzerra, INN-Ofatumumab
Provider Bulletin Clinical Criteria Updates
Genmab Announces That Janssen Has Submitted a Biologics License Application to U.S
Medical Drug Benefit Clinical Criteria Updates
Copy of New Century Health List of Changes to Drug Policies